By Jeff Siegel
These days, it’s hard to find issues that can unite this country.
But a couple weeks ago, we got one after the United States Anti-Doping Agency suspended Olympic hopeful Sha’Carri Richardson for one month after testing positive for cannabis.
Once this news broke, Americans from both sides of the aisle and all political and social ideologies took to social media to vent their frustrations.
How is it that a gifted Olympic-level athlete could have her dreams demolished because she consumed a plant that is legal throughout most of the country?
Moreover, where’s the compassion for this woman?
Turns out Richardson had consumed cannabis in an effort to cope with the unexpected death of her biological mother while she was in Oregon for the Olympic trials.
So when I saw the outpouring of support for Sha’Carri Richardson, I was beyond pleased — not just because it was deserved but because it provided further evidence that the majority of people in this country oppose the prohibition of cannabis.
We already knew this to be true, but to see so many Americans become so vocal about it really sent a powerful message to lawmakers. And those lawmakers took notice, with politicians from both major parties opining on the matter.
From New York Democrat Alexandria Ocasio-Cortez to Texas Republican Dan Crenshaw, there was a rare instance of bipartisan agreement centered around Richardson’s suspension.
And what’s particularly exciting is that this will absolutely carry over into the next election cycle.
Bottom line: Americans are fed up with the prohibition of cannabis. It's irrational, nonsensical, and a wasted opportunity to help build local economies while serving as a catalyst for real criminal justice reform.
While I don’t know what Richardson’s future holds, I do know that her suspension only helped to expedite the descheduling and federal legalization of cannabis.
This is good for society, this is good for our economy, and this is good for investors who have some portion of their portfolios dedicated to the cannabis sector, which will only continue to become more and more valuable as the weeks, months, and years progress.
While there are dozens of cannabis stocks to choose from, I remain particularly bullish on Curaleaf CURLF, MariMed MRMD, Red White & Bloom RWBYF, and Innovative Industrial Properties IIPR.
Encuentra nuestro contenido en Español en El Planteo:
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.
All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.
Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.
Rate collection and criteria: Click here for more information on rate collection and criteria.